HUTCHMED (NASDAQ:HCM) Shares Gap Down – Time to Sell?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $15.09, but opened at $14.64. HUTCHMED shares last traded at $14.70, with a volume of 6,976 shares.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Friday.

HUTCHMED Price Performance

The company has a fifty day moving average price of $14.70 and a two-hundred day moving average price of $16.48. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of HCM. State Street Corp boosted its holdings in shares of HUTCHMED by 0.9% during the third quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after acquiring an additional 3,078 shares during the period. Renaissance Technologies LLC boosted its stake in HUTCHMED by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company’s stock valued at $2,717,000 after purchasing an additional 29,239 shares during the period. Jane Street Group LLC grew its holdings in HUTCHMED by 54.7% in the 4th quarter. Jane Street Group LLC now owns 97,470 shares of the company’s stock valued at $1,405,000 after buying an additional 34,473 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in HUTCHMED by 99.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after buying an additional 24,245 shares during the period. Finally, XY Capital Ltd acquired a new stake in shares of HUTCHMED during the fourth quarter worth $673,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.